Peptide Research Week in Review: 9-15 September 2026
TL;DR: This week: UCLA's 565-study peptide evidence review and Corbus's oral CRB-913 obesity trial data, a non-incretin rival to GLP-1-class research.
What Happened in Peptide Research This Week (9-15 Sep 2026)?
A quieter week than most, with two items doing the heavy lifting rather than a broad spread of stories. UCLA orthopaedic-surgery researchers published a systematic review of 565 studies covering six popular unapproved research peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu — in the American Journal of Sports Medicine, first covered by UCLA Health and trade press on 8 September 2026.[1] And on 14 September 2026, Corbus Pharmaceuticals reported positive Phase 1b topline results from CANYON-1, its trial of CRB-913, a daily oral, peripherally restricted CB1 inverse agonist for obesity — a non-incretin mechanism entirely distinct from the GLP-1/GIP/glucagon pathway that retatrutide and its research-peptide relatives target.[4]
Retatrutide itself had no dedicated trial readout this week. Eli Lilly's most recent milestone remains the 23 July 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results, with a Biologics License Application submission to the FDA still targeted for Q1 2027.[5] The two stories below matter for retatrutide-adjacent research anyway: one is a direct evidence-quality audit of the compound class most Velox customers research, and the other is a live example of how a well-controlled, multi-site, placebo-controlled Phase 1b obesity trial is actually run and reported — a useful contrast for reading the peptide literature critically.
What Did UCLA's 565-Study Peptide Review Find?
Scope: The review covered 565 published studies across six compounds widely sold and discussed in wellness and sports-recovery contexts. More than two-thirds of the studies identified were animal-only; the human research that did exist was described by the authors as generally low quality.[1]
Conflict of interest flag: One of the most frequently cited BPC-157 studies in the wider literature was found to carry an undisclosed financial conflict of interest, a detail the reviewers highlighted as relevant to how confidently marketing claims built on that citation should be read.[2]
Safety signal: One MK-677 trial was stopped early after a congestive-heart-failure signal emerged — 6.5% of participants on MK-677 versus 1.7% on placebo — illustrating that "unapproved" and "unstudied for safety" are not the same claim, and that some of this compound class has been tested specifically because a safety question needed answering.[1]
Headline conclusion: The reviewers concluded that marketing claims made for these compounds are, in their words, far ahead of the published science — a literature-quality judgment about the evidence base, not a finding that the compounds are unsafe or ineffective in every context studied.[1]
Full breakdown: UCLA's 565-Study Peptide Supplement Review (2026)
None of the six compounds in the UCLA review is a GLP-1/GIP/glucagon-class agonist, so the review says nothing directly about retatrutide's evidence base — which rests on its own, separately published Phase 1–3 programme.[3] But the underlying methodology point applies across the whole research-peptide category: study design, sample size, conflict-of-interest disclosure and human-versus-animal data all determine how much weight a given citation can bear, and researchers evaluating any compound in this space should read primary sources rather than summary marketing claims.
What Did the CRB-913 CANYON-1 Trial Report, and Why Does It Matter for GLP-1-Class Research?
Trial design: CANYON-1 enrolled 254 obese, non-diabetic adults across 15 US sites, randomised to daily oral CRB-913 at multiple doses versus placebo over 12 weeks.[4]
Efficacy: Corbus reported statistically significant, dose-dependent weight loss at all three doses studied, with the 60 mg dose producing a mean 5% weight reduction at 12 weeks.[4]
Safety and mechanism: CRB-913 is a peripherally restricted CB1 inverse agonist — a non-incretin mechanism, structurally and pharmacologically unrelated to GLP-1, GIP or glucagon receptor agonism. Corbus reported a favourable safety profile with fewer gastrointestinal adverse events on cross-trial comparison against published oral GLP-1 data, consistent with a mechanism that does not slow gastric emptying the way incretin-class compounds do.[4]
Next steps: Full data will be presented in a late-breaking session at ObesityWeek® 2026 (14–17 November 2026). Corbus plans to engage the FDA on a clinical development plan and expects to start a Phase 2 monotherapy study in the first half of 2027, alongside evaluating CRB-913 in combination with GLP-1 therapy.[4]
Full breakdown: CRB-913: A Non-Incretin Oral Obesity Drug
CRB-913 is a licensed pharmaceutical candidate in industry-sponsored clinical development, not a research peptide sold by Velox Peptides or any research-reagent supplier — it is a small molecule, not a peptide at all. It is included here because a peripherally restricted CB1 pathway is the first plausible non-incretin rival to reach human obesity data in this cycle, and the first-generation CB1 drug for obesity, rimonabant, was withdrawn in 2008/09 over psychiatric adverse events precisely because it crossed into the central nervous system.[4] Whether CRB-913's peripheral restriction genuinely avoids that liability at scale is a question Phase 2 and Phase 3 data, not a 12-week Phase 1b readout, will need to answer.
How Do This Week's Two Stories Connect?
One story is about evidence quality; the other is a demonstration of what strong evidence looks like. UCLA's review found the peptide literature behind BPC-157, TB-500 and similar compounds thin, mostly animal-only, and in at least one case compromised by an undisclosed conflict of interest. CANYON-1, by contrast, is a randomised, placebo-controlled, multi-site, 254-participant Phase 1b trial with a pre-registered design, industry sponsorship disclosed up front, and a defined path to Phase 2 — the same evidentiary standard retatrutide's own Phase 1–3 programme has followed.
Read together, the two stories are a useful reminder that "peptide" and "research compound" are not a single evidence tier. Retatrutide and CRB-913 sit inside conventional, disclosed, randomised drug-development programmes; several of the compounds in the UCLA review do not, and researchers should weigh citations accordingly rather than treating "published study exists" as equivalent to "well-controlled human trial."
What Happens Next?
| Track | Next milestone | Expected timing |
|---|---|---|
| CRB-913 (Corbus) | Full CANYON-1 data, late-breaking presentation | ObesityWeek®, 14-17 Nov 2026 |
| CRB-913 (Corbus) | Phase 2 monotherapy study start | H1 2027 |
| FDA 503A Bulks List (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) | Final rulemaking after July 2026 PCAC vote | No date announced |
| Retatrutide BLA (Lilly) | FDA filing submission | Q1 2027 |
| Velox Peptides | Next weekly research roundup | 22 September 2026 |
What Should UK and Irish Researchers Take From This Week?
Neither story changes the regulatory status of research peptides in the UK or Ireland. UCLA's review is a literature-quality assessment, not a regulatory action, and does not alter any compound's legal classification. CRB-913 is an investigational small-molecule drug candidate in industry-sponsored clinical development — it is not sold as a research reagent by Velox Peptides or any comparable supplier. See our guide on whether research peptides are legal in the UK for the fuller regulatory picture, and retatrutide's mechanism of action for how a GLP-1/GIP/glucagon triple agonist compares pharmacologically to a peripherally restricted CB1 inverse agonist like CRB-913.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA, HPRA or FDA. Not for human or veterinary consumption. See our Research Use Policy and MHRA Statement.
References
- Partnership for Safe Medicines. September 8, 2026: Researchers say evidence that peptides are effective "is just not there." safemedicines.org, recapping UCLA Health's coverage of a 565-study review of BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu published in the American Journal of Sports Medicine, 2026. Full breakdown: veloxpeps.com
- Velox Peptides. UCLA's 565-Study Peptide Supplement Review (2026) — conflict-of-interest and evidence-quality detail. veloxpeps.com
- Velox Peptides. Retatrutide Clinical Research: Phase 1 & Phase 2 Trial Data. veloxpeps.com
- Corbus Pharmaceuticals. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity. Press release, 14 September 2026. globenewswire.com. Full breakdown: veloxpeps.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. Press release, 23 July 2026. investor.lilly.com
- Velox Peptides. Peptide Research Week in Review: 2-8 September 2026, for the preceding week's coverage. veloxpeps.com
Frequently Asked Questions
What's the biggest peptide research story this week (9-15 September 2026)?
Two items dominated. UCLA orthopaedic-surgery researchers published a 565-study review in the American Journal of Sports Medicine finding weak, mostly animal-only evidence behind BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. And Corbus Pharmaceuticals reported positive Phase 1b CANYON-1 topline data for CRB-913, a daily oral, peripherally restricted CB1 inverse agonist for obesity, in 254 participants across 15 US sites.
Did retatrutide have any news this week?
No dedicated retatrutide readout published this week. Eli Lilly's most recent retatrutide milestone remains the 23 July 2026 TRIUMPH-2 and TRIUMPH-3 topline results, with a Biologics License Application submission still targeted for Q1 2027. This week's most relevant story for retatrutide-class research was CRB-913, a non-incretin oral candidate being developed as a potential alternative or combination partner to GLP-1-class compounds. Order HPLC-verified retatrutide for research →
What did the UCLA peptide review actually find?
Reviewing 565 studies of six popular unapproved peptides, UCLA researchers found more than two-thirds were animal-only, human data were generally low quality, a widely cited BPC-157 study carried an undisclosed financial conflict of interest, and one MK-677 trial was halted early after a congestive-heart-failure safety signal (6.5% vs 1.7% on placebo). The review concluded that marketing claims for these compounds are far ahead of the published science.
Does any of this week's news affect UK research-reagent supply?
No. The UCLA review is a literature-quality assessment of published studies and does not change any compound's UK legal status. Corbus's CRB-913 is an investigational small-molecule drug in Phase 1b development, not a peptide, and is not sold by Velox Peptides. Every compound Velox Peptides supplies remains an HPLC-verified in vitro research reagent only, regulated under the UK's Human Medicines Regulations 2012.